KBI Biopharma Partners with Infinimmune to Advance Human-First Antibody Manufacturing for Atopic Dermatitis
Key Insights
KBI Biopharma (search) and Infinimmune (search) have announced a collaboration to advance manufacturing of IFX-101 (search), a human monoclonal antibody targeting atopic dermatitis (search) designed for superior efficacy with extended dosing intervals.
Infinimmune (search)'s GLIMPSE platform uses a protein language model trained on native human antibody sequences to engineer antibodies that harness evolution-proven strategies with enhanced biologic properties.
The IFX-101 (search) program is progressing at KBI's Cell Line Development Center of Excellence in Geneva, Switzerland, utilizing the company's SUREmAb monoclonal antibody development and manufacturing platform.
KBI Biopharma (search), Inc., a JSR Life Sciences (search) company and cGMP contract development and manufacturing organization (CDMO), has announced a strategic collaboration with biotechnology company Infinimmune (search), Inc. to advance manufacturing of Infinimmune's lead human monoclonal antibody program, IFX-101 (search), targeting atopic dermatitis (search).
Novel Human-First Antibody Approach
The first antibody in Infinimmune (search)'s therapeutic drug development pipeline, IFX-101 (search), is designed to deliver superior efficacy with extended dosing intervals for improved patient quality of life. Unlike traditional antibody engineering approaches, Infinimmune sources antibodies directly from the human immune system, tapping into what the company describes as a naturally optimized, safe, and effective therapeutic reservoir rather than engineering from scratch.
Central to Infinimmune (search)'s approach is its GLIMPSE™ platform, a protein language model trained solely on native human antibody sequences. The platform learns from millions of successful immune responses to engineer superior antibodies that harness evolution-proven strategies with enhanced biologic properties. According to the company, this combination creates a potent platform that's uniquely differentiated in the biologics field.
Manufacturing Partnership Details
The IFX-101 (search) program is progressing at KBI's Cell Line Development Center of Excellence in Geneva, Switzerland, utilizing KBI's advanced monoclonal antibody development and manufacturing platform, SUREmAb™, powered by Selexis (search).
"We are pleased to partner with KBI Biopharma (search) to advance our lead antibody program," said Wyatt McDonnell, Ph.D., CEO and Co-Founder of Infinimmune (search). "By combining our Anthrobody® and GLIMPSE™ platforms together with KBI's development and manufacturing expertise, we're positioned to rapidly advance toward clinical trials. Our human-first approach enables us to deliver what patients really need – more effective treatments with greater convenience."
Katie Edgar, Chief Business Officer of KBI Biopharma (search), emphasized the synergistic nature of the partnership: "KBI is proud to support Infinimmune (search) in its effort to transform biologics and deliver safer, more effective antibody therapeutics. Our strategic partnership will be highly synergistic in biologics development, by combining Infinimmune's cutting-edge antibody discovery with KBI's deep expertise in development and manufacturing capabilities."
Company Backgrounds
Infinimmune (search) is building its own pipeline of drug candidates while also partnering with pharmaceutical companies to advance their antibody programs. The company's platform combines its Anthrobody® technology with the GLIMPSE™ system to deliver antibody drugs derived directly from the human immune system.
KBI Biopharma (search) serves as a global leader in mammalian cell line development, working with over 500 customer partners to advance more than 170 drug candidates in preclinical and clinical development, as well as manufacturing ten commercial products. The company operates six locations across Europe and the USA, providing fully integrated drug development and biologics manufacturing services.